ORIC insider buying and SEC filings, explained
Oric Pharmaceuticals, Inc. · CIK 1796280
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$497K
Planned sales (10b5-1)
$2.5M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 20, 2026 | Planned (10b5-1) | Dominic Piscitelli (CFO) sold 14,000 shares at about $13.53 ($189K), marked as a 10b5-1 plan trade. Holdings down 17% to 69,828 shares. | SEC filing Filed Oct 21, 2026, 5:17 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Richard A. Heyman (Director) sold 6,700 shares directly and indirectly at $12.91 ($87K), marked as a 10b5-1 plan trade. Direct holdings down 8% to 38,300 shares. | SEC filing Filed Oct 2, 2026, 5:50 PM ET |
| Sep 28, 2026 | Planned (10b5-1) | Dominic Piscitelli (CFO) sold 13,400 shares at about $13.53 ($181K), marked as a 10b5-1 plan trade. Holdings down 16% to 69,828 shares. | SEC filing Filed Sep 29, 2026 |
| Sep 24, 2026 | Planned (10b5-1) | Dominic Piscitelli (CFO) sold 600 shares at about $13.51 ($8K), marked as a 10b5-1 plan trade. Holdings down 1% to 69,828 shares. | SEC filing Filed Sep 25, 2026 |
| Aug 26, 2026 | Planned (10b5-1) | Dominic Piscitelli (CFO) sold 77,000 shares at $13.69 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 52% to 69,828 shares. | SEC filing Filed Aug 28, 2026 |
| Jul 24, 2026 | Planned (10b5-1) | Richard A. Heyman (Director) sold 13,100 shares directly and indirectly at $12.02 ($157K), marked as a 10b5-1 plan trade. Direct holdings down 15% to 38,300 shares. | SEC filing Filed Jul 28, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Richard A. Heyman (Director) sold 300 shares indirectly at $12.00 ($4K), marked as a 10b5-1 plan trade. Indirect holdings down <1% to 212,772 shares. | SEC filing Filed Jul 8, 2026 |
| Feb 24, 2026 | Planned (10b5-1) | Dominic Piscitelli (CFO) sold 52,000 shares at about $13.51 ($703K), marked as a 10b5-1 plan trade. Holdings down 43% to 68,148 shares. | SEC filing Filed Feb 26, 2026 |
| Jan 16, 2026 | Planned (10b5-1) | Richard A. Heyman (Director) sold 6,700 shares directly and indirectly at about $12.00 ($80K), marked as a 10b5-1 plan trade. Direct holdings down 8% to 41,800 shares. | SEC filing Filed Jan 20, 2026 |
| Dec 16, 2025 | Sale | Dominic Piscitelli (CFO) sold 10,720 shares at about $9.06 ($97K). Holdings down 14% to 68,148 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 17, 2025 |
| Dec 16, 2025 | Sale | Jacob Chacko (CEO and Director) sold 33,374 shares at about $9.06 ($302K). Holdings down 5% to 581,711 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 17, 2025 |
| Dec 16, 2025 | Sale | Pratik S Multani (Chief Medical Officer) sold 10,720 shares at about $9.06 ($97K). Holdings down 14% to 68,149 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 17, 2025 |
20 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ORIC in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.